Not Yet RecruitingPhase 1

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

United States48 participantsStarted 2026-05-01

Plain-language summary

The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female
✓. Age 18-55 years (both inclusive) at the time of signing the informed consent.
✓. Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
✓. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator.

Exclusion criteria

✕. Known or suspected hypersensitivity to study intervention(s) or related products.
✕. Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
✕. Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) \[48 millimole per mole (mmol/mol)\] at screening.

What they're measuring

Number of treatment emergent adverse events (TEAEs)

Timeframe: From time of dosing (day 1) up to day 43

Trial details

NCT IDNCT07566390

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-11-26

Contact for this trial

Novo Nordisk

(+1) 866-867-7178 clinicaltrials@novonordisk.com

View on ClinicalTrials.gov More Obesity trials